findmyKOL

Dara Koozekanani, MD, PhD

Basic profile

University of Minnesota

ORCIDNone on fileNPI
RegionMinneapolis, MN · MidwestSpecialtyOphthalmologyFocusOphthalmology
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPaymentsNone reportedNIH funding2024–2024Why? →

Dara Koozekanani is an Ophthalmology physician affiliated with University of Minnesota. OpenAlex indexes 92 publications with 3,033 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
92publications

Distinct works indexed by OpenAlex.

3,033citations

Total citations across indexed works.

21h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
1NIH grants · 2024–2024

Federally funded research awards.

View funding

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    95.6%
    Antineovascularisation agents90.7%
    Faricimab-svoa100%
    Part B, office-administered19 patients
    Prostaglandin Analog1.4%
    Latanoprost100%
    Part D25 patients

    + 5 more classes in this area

  • Cancer & immunology

    3.4%
    Vascular Endothelial Growth Factor Inhibitor3.4%
    Aflibercept81%Bevacizumab19%
    Part B, office-administered21 patients
  • Cardiovascular

    0.5%
    Beta blocker0.5%
    Timolol Maleate100%
    Part D16 patients
Where care is delivered (Part B)15.1% facility · 84.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20242024 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”